PDCD1 and hepatocellular carcinoma: Nivolumab (Opdivo, Bristol-Myers-Squibb) was the first anti-PD-1 mAb to be FDA-approved as a second-line treatment for HCC in combination with ipilimumab, as evidenced through the phase I/II CheckMate 040 trial [91].